Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer
Authors
Keywords
-
Journal
Targeted Oncology
Volume 15, Issue 3, Pages 377-390
Publisher
Springer Science and Business Media LLC
Online
2020-06-03
DOI
10.1007/s11523-020-00728-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
- (2019) Laurence Albiges et al. EUROPEAN UROLOGY
- Regulation of PD-1/PD-L1 Pathway in Cancer by Noncoding RNAs
- (2019) Lei Ding et al. PATHOLOGY & ONCOLOGY RESEARCH
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
- (2018) Diana Miao et al. SCIENCE
- Cancer immunoediting and resistance to T cell-based immunotherapy
- (2018) Jake S. O’Donnell et al. Nature Reviews Clinical Oncology
- Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer
- (2018) Ewelina Grywalska et al. OncoTargets and Therapy
- Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
- (2017) Matthew A. Coelho et al. IMMUNITY
- RAS and PD-L1: A Masters’ Liaison in Cancer Immune Evasion
- (2017) Nicole Glodde et al. IMMUNITY
- PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
- (2017) Michal Šmahel INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells
- (2017) Daniel Yee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
- (2017) Marian L. Burr et al. NATURE
- Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection
- (2017) Rileen Sinha et al. Nature Communications
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
- (2016) Joseph L. Benci et al. CELL
- Choosing the right cell line for renal cell cancer research
- (2016) Klaudia K. Brodaczewska et al. Molecular Cancer
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
- (2015) B Homet Moreno et al. BRITISH JOURNAL OF CANCER
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
- (2015) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy
- (2015) François Bertucci et al. Oncotarget
- Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial
- (2014) T. K. Choueiri et al. CLINICAL CANCER RESEARCH
- New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape
- (2014) Deepak Mittal et al. CURRENT OPINION IN IMMUNOLOGY
- MicroRNA-513 Regulates B7-H1 Translation and Is Involved in IFN- -Induced B7-H1 Expression in Cholangiocytes
- (2014) A.-Y. Gong et al. JOURNAL OF IMMUNOLOGY
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas
- (2011) B. D. Looyenga et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search